ACIU Capex Per Share from 2010 to 2024

ACIU Stock  USD 3.38  0.09  2.74%   
AC Immune Capex Per Share yearly trend continues to be comparatively stable with very little volatility. Capex Per Share is likely to outpace its year average in 2024. From the period from 2010 to 2024, AC Immune Capex Per Share quarterly data regression had r-value of  0.52 and coefficient of variation of  71.05. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.00945751
Current Value
0.0147
Quarterly Volatility
0.01114877
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AC Immune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AC Immune's main balance sheet or income statement drivers, such as Interest Expense of 167.2 K, Selling General Administrative of 8.3 M or Total Revenue of 20 M, as well as many indicators such as Price To Sales Ratio of 38.71, Dividend Yield of 0.0 or PTB Ratio of 2.11. ACIU financial statements analysis is a perfect complement when working with AC Immune Valuation or Volatility modules.
  
Check out the analysis of AC Immune Correlation against competitors.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

Latest AC Immune's Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of AC Immune over the last few years. It is AC Immune's Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AC Immune's overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Slightly volatile
   Capex Per Share   
       Timeline  

ACIU Capex Per Share Regression Statistics

Arithmetic Mean0.02
Geometric Mean0.01
Coefficient Of Variation71.05
Mean Deviation0.01
Median0.01
Standard Deviation0.01
Sample Variance0.0001
Range0.0328
R-Value0.52
Mean Square Error0.000098
R-Squared0.27
Significance0.05
Slope0
Total Sum of Squares0

ACIU Capex Per Share History

2024 0.0147
2023 0.009458
2022 0.0148
2021 0.0352
2020 0.0237
2019 0.0267
2018 0.03

About AC Immune Financial Statements

AC Immune shareholders use historical fundamental indicators, such as Capex Per Share, to determine how well the company is positioned to perform in the future. Although AC Immune investors may analyze each financial statement separately, they are all interrelated. The changes in AC Immune's assets and liabilities, for example, are also reflected in the revenues and expenses on on AC Immune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex Per Share 0.01  0.01 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.